Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021
|出版商||Frost & Sullivan||商品編碼||596064|
|出版日期||內容資訊||英文 81 Pages
|歐洲的產前基因檢測市場上成長的機會，至2021年的預測 Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021|
|出版日期: 2017年11月30日||內容資訊: 英文 81 Pages||
Non-invasive Prenatal Testing (NIPT) Driven by the Adoption of Next Generation Sequencing (NGS) Techniques for Screening is Driving Market Growth
Prenatal genetic tests are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, 13 and carrier screens. They are gaining momentum in EU due to enhanced assay outcomes through non-invasive methodologies using next generation sequencing (NGS) techniques, increasing number of women choosing to undergo pregnancy at an advanced maternal age (over 35 years) and considerable popularity through social media and e-commerce channels. High level of merger and acquisition activity apart from numerous collaborations with regional clinical labs has supported the participants in marketing their products across the European region. Moreover, companies are also exploring new avenues to market their product by strategically tying up with IVF clinics, physicians, genetic counsellors and OBGYNs. Partnership with big data companies is anticipated to be the next big leap in the prenatal genetic testing market, thereby providing interpretation of vast volumes of data to increase specificity, sensitivity, and cost of tests. The key business model emerging across the market is the collaboration of key participants with regional private clinical labs as well as public centres and organizations such as NHS to increase the market coverage in Europe.
The key objectives of this growth insights study are to track the transformations in the prenatal genetic test market landscape in Europe for 2016-2021. The study aims at identifying growth opportunities across the market and suggesting most profitable business models to market players. Furthermore, the study provides an in-depth revenue and market analysis of 4 key segments within the prenatal landscape: NIPT, carrier screening for cystic fibrosis, invasive tests, and miscarriage tests. The study highlights industry challenges, growth drivers, restraints, competitive developments, key mergers and acquisitions (M&As), and investment opportunities. Key trends across the market with respect to physician and patient attitudes toward prenatal genetic screening and its probable impact on growth are analyzed. Additionally, top growth opportunities, profiles of game-changing companies, disruptive technologies and innovative business models, along with strategic recommendations are included.